Ketosis Prone Diabetes in African-Americans
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00426413|
Recruitment Status : Completed
First Posted : January 24, 2007
Last Update Posted : November 13, 2013
|Condition or disease||Intervention/treatment|
|Ketosis Prone Diabetes Diabetic Ketoacidosis Severe Hyperglycemia||Drug: pioglitazone|
|Study Type :||Observational|
|Estimated Enrollment :||44 participants|
|Official Title:||Ketosis Prone Diabetes Mellitus in African-Americans: Insulin Signaling, Proteomics, and Outcomes|
|Study Start Date :||May 2007|
|Actual Primary Completion Date :||August 2010|
|Actual Study Completion Date :||August 2010|
Obese AA subjects with DKA or severe hyperglycemia
Obese AA subjects with DKA or severe hyperglycemia that are able to discontinue insulin at 12 weeks or less will be randomized (blinded fashion) to receive either placebo or pioglitazone qd. The subjects will be followed while in the study arm and beta-cell function will be assessed using OGTT at set intervals.
Other Name: Actos (pioglitazone)
obese nondiabetic subjects, age 19-65.
Any subjects with recurrent DKA. Recurrent DKA is defined as more than one admission to Grady Memorial Hospital.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00426413
|United States, Georgia|
|Grady Memorial Hospital|
|Atlanta, Georgia, United States, 30303|
|Principal Investigator:||Dawn D Smiley, MD||Emory University|